ArticleOncogene2013
microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin.
Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- MicroRNA-125b in vascular diseases: An updated systematic review of pathogenetic implications and clinical applications.Journal of cellular and molecular medicine · 2019Pooled it
- The interplay of integrin, VE-cadherin, and β-catenin signaling triad in angiogenesis: regulation by Wnt antagonist, secreted frizzled related protein 4 in the tumor angiogenic loop.Medical oncology (Northwood, London, England) · 2026Review
- An integrative clinical and bioinformatic analysis identifies MicroRNAs as biomarkers of ischemic stroke severity.Scientific reports · 2026Article
- Dietary inulin supplementation in early gestation regulates uterine fluid exosomes and angiogenesis to improve embryo implantation in sows.Journal of animal science and biotechnology · 2025Article
- Engineering extracellular vesicles to transiently permeabilize the blood-brain barrier.Journal of nanobiotechnology · 2024Article
- Over-expression of miR-183-5p or miR-492 triggers invasion and proliferation and loss of polarity in non-neoplastic breast epithelium.Scientific reports · 2022Article
- Long Non-coding RNAs: Pivotal Epigenetic Regulators in Diabetic Retinopathy.Current genomics · 2022Review
- Non-coding RNAs in lung cancer: emerging regulators of angiogenesis.Journal of translational medicine · 2022Review
- Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance.Nanomedicine (London, England) · 2022Review
- LncRNA NNT-AS1 regulates proliferation, ECM accumulation and inflammation of human mesangial cells induced by high glucose through miR-214-5p/smad4.BMC nephrology · 2021Article
- Long non-coding RNA MALAT1 enhances angiogenesis during bone regeneration by regulating the miR-494/SP1 axis.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Potential of Long Non-Coding RNAs in Age-Related Macular Degeneration.International journal of molecular sciences · 2021Review
- Genistein alleviates chronic vascular inflammatory response via the miR‑21/NF‑κB p65 axis in lipopolysaccharide‑treated mice.Molecular medicine reports · 2021Article
- A risk progression breast epithelial 3D culture model reveals Cx43/hsa_circ_0077755/miR-182 as a biomarker axis for heightened risk of breast cancer initiation.Scientific reports · 2021Article
- Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies.International journal of molecular sciences · 2021Review
- Knockdown of LncRNA SNHG1 Suppresses Corneal Angiogenesis by the Regulation of miR-195-5p/VEGF-A.Journal of ophthalmology · 2021Article
- MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.Frontiers in oncology · 2021Review
- Gap Junctions between Endothelial Cells Are Disrupted by Circulating Extracellular Vesicles from Sickle Cell Patients with Acute Chest Syndrome.International journal of molecular sciences · 2020Article
- Artesunate inhibits osteoclastogenesis through the miR-503/RANK axis.Bioscience reports · 2020Article
- The Epigenetic Profile of Tumor Endothelial Cells. Effects of Combined Therapy with Antiangiogenic and Epigenetic Drugs on Cancer Progression.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is controlled positively or negatively by extrinsic and intrinsic molecular cues in endothelial cells (ECs); in the tumor microenvironment, the action of positive regulators exceeds that of negative regulators. Thus, overinduction of negative regulators may inhibit tumor angiogenesis. MicroRNAs (miRNAs or miRs) are endogenous short noncoding RNAs regulating gene expression either through translational inhibition or destabilization of target mRNA. Here, we show that miR-125b expression is transiently induced in ECs on stimulation with vascular endothelial growth factor or by ischemia. miR-125b inhibits translation of vascular endothelial (VE)-cadherin mRNA and in vitro tube formation by ECs. Injection of miR-125b into the tumor inhibited VE-cadherin expression by ECs and induced nonfunctional blood vessel formation, resulting in inhibition of tumor growth. It has been suggested that pro-angiogenic signals in ECs also upregulate anti-angiogenic molecules simultaneously via negative feedback. Because miR-125b induction in ECs is transient after pro-angiogenic stimulation, prolonged overexpression of miR-125b could result in blood vessel regression. Thus, miR-125b may be useful in cancer therapy by causing the collapse of the lumen of ECs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.